Skip to main content
. 2016 May 26;7(28):43588–43603. doi: 10.18632/oncotarget.9635

Table 1. Clinical parameters of the HCC patients included in this study.

Clinical parameters CPS1-IT1 < 2.65 CPS1-IT1 > 2.65
N(%) N(%)
Total number of patients 62(52.1) 57(47.9)
Gender
 Male 53(85.5) 48(84.2)
 Female 9(14.5) 9(15.8)
Age
 < 55 25(40.3) 20(35.1)
 > 55 37(59.7) 37(64.9)
Smoking
 Negative 35(58.3) 36(64.3)
 Positive 25(41.7) 20(35.7)
Alcoholism
 Negative 39(66.1) 39(76.5)
 Positive 20(33.9) 12(23.5)
HBV
 Negative 3(4.8) 2(3.6)
 Positive 59(95.2) 54(96.4)
HCV
 Negative 2(3.2) 1(1.8)
 Positive 60(96.8) 56(98.3)
Bilirubin
 < 0.9 31(50.0) 32(56.1)
 > 0.9 31(50.0) 25(43.9)
AST
 < 52 41(67.2) 40(72.7)
 > 52 20(32.8) 15(27.3)
ALT
 < 111 52 (86.7) 46(86.8)
 > 111 8(13.3) 7(13.2)
Alb
 < 4 28(45.2) 23(40.4)
 > 4 34(54.8) 34(59.7)
Cr
 < 1 22(36.7) 18(32.1)
 > 1 38(63.3) 38(67.9)
AFP
 < 10 17(27.9) 18(33.3)
 > 10 44(72.1) 36(66.7)
Tumor size
 < 3 22(35.5) 15(26.3)
 > 3 40(64.5) 42(73.7)
Capsule invasion
 Absence 6(9.7) 7(12.3)
 Presence 56(90.3) 50(87.7)
Vessel invasion
 Absence 25(40.3) 24(42.1)
 Presence 37(59.7) 33(57.9)
Stage
 < 2 43(69.4) 38(66.7)
 > 2 19(30.7) 19(33.3)